Company
Arcutis
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
2
2 still marketed
Novel approvals
0
Approvals since 2021
7
Originals and new uses
Phase 3 trials
10
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
Drugs in development (0)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials under this sponsor name.
Recruiting Phase 3 trials
Largest first.
- Roflumilast Cream 0.3% for Moderate to Severe Atopic DermatitisPivotal-lookingRecruiting
Arcutis Biotherapeutics, Inc.Industry
NCT07916480 · 415 participants (planned) · Start Oct 30, 2026 · Primary completion Apr 27, 2028
Drug: Roflumilast Cream 0.3%; Vehicle Cream · For: Atopic Dermatitis; Atopic Dermatitis (AD); Atopic Dermatitis (Eczema)
Sites: Birmingham, Alabama; Bryant, Arkansas; Miami Lakes, Florida · 4 sites in all
Marketed drugs (2)
Newest FDA action first.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.